Reason for request
Inclusion on the list of medicines refundable by National Health Insurance and approved for hospital use.
Clinical Benefit
| Substantial |
The actual benefit of ZYTIGA is substantial. |
Clinical Added Value
| moderate |
ZYTIGA provides a moderate improvement in actual benefit (level III) in terms of efficacy and tolerance in the treatment of metastatic castration-resistant prostate cancer which progresses during or after docetaxel therapy. |
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
MyEUxghCtB1r3BeR
